NCT06468774 Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
| NCT ID | NCT06468774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Chronic Mesenteric Ischemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-06-10 |
| Primary Completion | 2037-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2024-06-10 with a primary completion date of 2037-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.
Eligibility Criteria
Inclusion Criteria: Above 18 years and has given informed written consent for treatment and study participation For the patient groups : Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment. Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment. For the control group: Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy. Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound. Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound. Exclusion Criteria: Age less than 18 years Has nor given written consent. \-
Contact & Investigator
Syed Sajid Hussain Kazmi, MD, PhD
PRINCIPAL INVESTIGATOR
Department of vascular surgery, Oslo University Hospital
Frequently Asked Questions
Who can join the NCT06468774 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Mesenteric Ischemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06468774 currently recruiting?
Yes, NCT06468774 is actively recruiting participants. Contact the research team at sshkazmi@gmail.com for enrollment information.
Where is the NCT06468774 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT06468774 clinical trial?
NCT06468774 is sponsored by Oslo University Hospital. The principal investigator is Syed Sajid Hussain Kazmi, MD, PhD at Department of vascular surgery, Oslo University Hospital. The trial plans to enroll 180 participants.